Overcoming of Microenvironment Protection on Primary Chronic Lymphocytic Leukemia Cells after Treatment with BTK and MDM2 Pharmacological Inhibitors

Overcoming of Microenvironment Protection on Primary Chronic Lymphocytic Leukemia Cells after Treatment with BTK and MDM2 Pharmacological Inhibitors

In B-chronic lymphocytic leukemia (B-CLL), the interaction between leukemic cells and the microenvironment promotes tumor cell survival. The Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib is one of the first-in-class molecules for the treatment of B-CLL patients; however, the emerging mechanisms...

Full description

Bibliographic Details
Main Authors: Erika Rimondi, Elisabetta Melloni, Arianna Romani, Veronica Tisato, Fabio Casciano, Gian Matteo Rigolin, Daniela Milani, Claudio Celeghini, Giorgio Zauli, Paola Secchiero, Rebecca Voltan
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Current Oncology
Subjects:
leukemia
MDM2 inhibitor
BTK inhibitor
p53
apoptosis
Online Access:https://www.mdpi.com/1718-7729/28/4/223

Internet

https://www.mdpi.com/1718-7729/28/4/223

Similar Items